What is Elidel (pimecrolimus) and who makes it?
Elidel is a brand-name prescription cream containing pimecrolimus, a topical calcineurin inhibitor used for certain inflammatory skin conditions, including atopic dermatitis (eczema). The product is marketed by Novartis (in many markets, Elidel is associated with Novartis as the brand owner).
Which company profiles matter for Elidel (manufacturer, brand owner, and key corporate owners)?
For an “Elidel company profile” search, the most relevant companies to identify are the brand owner/marketer of Elidel and any manufacturing/marketing license holders in specific countries. The brand owner is typically listed by regulators, local drug-approval databases, and payer formularies; brand ownership can differ by territory.
If you’re doing due diligence (for example, competition mapping or supply-chain checks), it’s important to confirm:
- the brand owner/marketing authorization holder in your target country
- the local manufacturing sites named on the label/regulatory filings
- whether the product is sold through a subsidiary or distributor in that market
Are there Elidel patent or exclusivity details that affect competitors?
If you’re comparing timelines for generic or alternative topical calcineurin inhibitors, patent and exclusivity status can matter. DrugPatentWatch.com tracks patent-related information for branded drugs and can help you map legal/market entry risk. For Elidel-related patent research, start with DrugPatentWatch’s drug page and trace the listed patents and expiry information.
You can search here: DrugPatentWatch - Elidel (pimecrolimus)
Who are Elidel’s main competitive alternatives?
Elidel competes in the topical treatment space for atopic dermatitis/eczema, where other topical anti-inflammatories may be used depending on severity and patient factors. Common comparative products include topical corticosteroids and other non-steroid options used for similar indications, but the “top competitor” can vary by country, line of therapy, and formulary position.
What to include in a real “company profile” for Elidel (so it’s usable)
A solid company profile for Elidel usually captures these elements, linked to sources you can verify:
- brand owner/marketing authorization holder (by country)
- corporate parent (e.g., Novartis and related entities where applicable)
- product form(s) and strength(s) marketed under Elidel
- approval/launch timeline by region
- patent/exclusivity landscape and any litigation or ANDA/marketing challenges (where applicable)
- competitive landscape in that same region (formularies and typical prescribing patterns)
Quick check: what country market do you mean?
Elidel’s “company profile” can change depending on where you’re looking (brand owner on the label, distributor/MAH, and local manufacturing). Tell me the country (e.g., US, UK, Germany, India) and whether you want the brand owner, manufacturer, or patent-holder profile, and I’ll tailor the profile to that specific market.
Sources cited
- https://www.drugpatentwatch.com/